EGFR and neoplasm: Among the synthetic agents evaluated in vivo, Zotarolimus and 20(S)-Protopanaxadiol (PPD) exhibit the strongest therapeutic potential based on their ability to suppress key oncogenic pathways —including EGFR, VEGF, NF-κB, and MAPK/ERK—and significantly reduce tumor burden in CRC xenograft models.